Puma Biotechnology, Inc. (PBYI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Puma Biotechnology, Inc. (PBYI) Healthcare & Pipeline Overview

Puma Biotechnology, Inc. is a biopharmaceutical firm specializing in the development and commercialization of cancer therapies, primarily focused on its lead drug Neratinib for HER2-positive breast cancer. With licensing agreements spanning globally, Puma aims to enhance cancer treatment outcomes and expand its therapeutic applications.

What Is the Investment Thesis for PBYI?

Puma Biotechnology presents a focused investment opportunity within the biotechnology sector, primarily driven by the potential of Neratinib. With a P/E ratio of 16.3 and a profit margin of 10.7%, Puma demonstrates current profitability. Key growth catalysts include expanding Neratinib's indications and penetrating new geographic markets through existing licensing agreements. The company's gross margin of 74.5% suggests strong pricing power. However, investors should be aware of the risks associated with pharmaceutical development, including regulatory hurdles and competition from other cancer therapies. Successful clinical trials and regulatory approvals for new indications are critical for future growth.

Based on FMP financials and quantitative analysis

PBYI Key Highlights

Market capitalization of $476M reflects investor valuation of Puma Biotechnology's current and future potential.

• P/E ratio of 16.3 indicates the company's profitability relative to its stock price.
• Gross margin of 74.5% demonstrates efficient cost management in producing and selling its products.
• Profit margin of 10.7% shows the percentage of revenue that turns into profit after all expenses, including cost of goods sold, are deducted.
• Beta of 1.18 suggests that Puma Biotechnology's stock is slightly more volatile than the overall market.

Who Are PBYI's Competitors?

PBYI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PBYI's Key Strengths?

Approved drug (Neratinib) for HER2-positive breast cancer.

• Established licensing agreements for global distribution.
• Experienced management team.
• Strong gross margin.

What Are PBYI's Weaknesses?

Reliance on a single product (Neratinib).

• Competition from established pharmaceutical companies.
• Potential for generic competition upon patent expiration.
• Relatively small company size.

What Could Drive PBYI Stock Higher?

Potential FDA approval for Neratinib in new indications (e.g., HER2 mutation-positive solid tumors).

• Ongoing clinical trials evaluating Neratinib in combination with other therapies.
• Expansion of licensing agreements to new geographic regions.
• Publication of clinical trial data supporting the efficacy of Neratinib.

What Are the Key Risks for PBYI?

Financial-distress signal — its Altman Z-Score of -1.70 sits in the distress zone (elevated bankruptcy risk).

• Insider selling — insiders were net sellers of roughly $1.1M recently.
• Regulatory setbacks or delays in obtaining approvals for new indications.
• Unsuccessful clinical trial results.
• Competition from other cancer therapies.
• Patent expiration and generic competition.
• Reliance on a single product (Neratinib).

What Are the Growth Opportunities for PBYI?

• Expanding Neratinib's Indications: Puma has the opportunity to expand the use of Neratinib beyond its current approved indication for early-stage HER2-overexpressed/amplified breast cancer. Investigating Neratinib for HER2 mutation-positive solid tumors could significantly broaden its market reach. The market for solid tumor therapies is substantial, with a global market size estimated at billions of dollars. Success in clinical trials and subsequent regulatory approvals are crucial for realizing this growth opportunity. Timeline: Ongoing clinical trials with potential data readouts within the next 2-3 years.
• Geographic Expansion Through Licensing Agreements: Puma's existing licensing agreements with companies like Specialised Therapeutics Asia Pte Ltd. and CANbridge BIOMED Limited provide a pathway for geographic expansion. These partnerships allow Puma to enter new markets without significant direct investment. The global market for cancer therapies is expanding, particularly in Asia. Successful execution of these partnerships is key to unlocking this growth potential. Timeline: Ongoing, with potential for increased revenue generation within the next 1-2 years.
• Combination Therapies: Exploring Neratinib in combination with other cancer therapies represents another growth opportunity. The combination of Neratinib with capecitabine for advanced or metastatic HER2-positive breast cancer is one such example. Combination therapies can often improve treatment outcomes and address drug resistance. The market for combination cancer therapies is growing, driven by the need for more effective treatments. Timeline: Ongoing clinical trials with potential data readouts within the next 2-3 years.
• Strategic Acquisitions or Partnerships: Puma could pursue strategic acquisitions or partnerships to expand its product pipeline or access new technologies. Acquiring complementary assets or partnering with other biotechnology companies could accelerate growth and diversify risk. The biotechnology industry is characterized by frequent mergers and acquisitions. Successful execution of such deals requires careful due diligence and integration. Timeline: Opportunistic, depending on market conditions and available opportunities.
• Direct Sales Force Expansion: While Puma currently relies on partnerships for some geographic regions, expanding its direct sales force in key markets could enhance its commercial capabilities. A direct sales force allows for greater control over marketing and sales efforts. The market for cancer therapies is highly competitive, and effective commercialization is essential for success. Timeline: Potential expansion within the next 3-5 years, contingent on market analysis and financial resources.

What Are PBYI's Competitive Advantages?

• Patent protection for Neratinib, providing exclusivity in key markets.
• Established licensing agreements with global pharmaceutical companies, expanding market reach.
• Clinical data supporting the efficacy and safety of Neratinib.
• Expertise in developing and commercializing cancer therapies.

What Does PBYI Do?

Puma Biotechnology, Inc., founded in 2010 and headquartered in Los Angeles, California, is a biopharmaceutical company dedicated to innovating cancer care. The company's primary focus is on the development and commercialization of PB272 neratinib (oral), a kinase inhibitor. Neratinib is approved for use in patients with early-stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. Puma is also investigating neratinib in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer, as well as for HER2 mutation-positive solid tumors. The company operates both in the United States and internationally, collaborating with partners through licensing and sub-licensing agreements. These agreements include partnerships with Pfizer, Inc., Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd., expanding the global reach of its therapies.

What Products and Services Does PBYI Offer?

• Develop and commercialize pharmaceutical products for cancer treatment.
• Focus on therapies for HER2-positive breast cancer and other solid tumors.
• Market Neratinib (PB272), an oral kinase inhibitor, for early-stage HER2-overexpressed/amplified breast cancer.
• Conduct clinical trials to evaluate Neratinib in combination with other therapies.
• Establish licensing agreements with other pharmaceutical companies for global distribution.
• Seek regulatory approvals for new indications and markets.

How Does PBYI Make Money?

• Develop proprietary cancer therapies.
• Commercialize approved therapies through direct sales and marketing in some regions.
• License and sub-license rights to other companies for distribution in specific territories.
• Generate revenue from product sales and licensing fees.

What Industry Does PBYI Operate In?

Puma Biotechnology operates within the competitive biotechnology industry, which is characterized by rapid innovation and stringent regulatory requirements. The market for cancer therapies is substantial and growing, driven by an aging population and increased cancer incidence. Puma's focus on HER2-positive breast cancer positions it within a specific niche of this market. Competition includes established pharmaceutical companies and other biotechnology firms developing similar therapies. Success in this industry requires strong research and development capabilities, successful clinical trials, and effective commercialization strategies.

Who Are PBYI's Key Customers?

• Patients with HER2-positive breast cancer.
• Oncologists and other healthcare professionals who prescribe cancer therapies.
• Hospitals and cancer treatment centers.
• Pharmaceutical companies that license Puma's products.

Company Profile

Puma Biotechnology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Alan H. Auerbach. PBYI has traded publicly since 2012.

Return on equity for Puma Biotechnology, Inc. stands at 20.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 13.9%, showing how much profit it generates from its asset base. PBYI trades at a trailing price-to-earnings ratio of 16.29, below the Healthcare sector average of ~23x. Its free cash flow yield is 9.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.9%, the inverse of the P/E and a quick read on earnings relative to price.

PBYI Valuation & Market Position

With a $476M market cap, Puma Biotechnology, Inc. sits in the small-cap segment of the market. Relative to its peer group, PBYI's quantitative score of 34/100 is below the peer average of 81/100.

Quarterly Financial Performance: Puma Biotechnology, Inc.

Revenue for Puma Biotechnology, Inc. came in at $56.5M during Q2 2026, a 26.1% improvement versus the preceding quarter. The company recorded net income of $8.2M, with diluted EPS of $0.16. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, PBYI averaged $0.13 in diluted EPS.

Puma Biotechnology, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of -1.70 places it in the distress zone, a signal of elevated financial risk.

Puma Biotechnology, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 172.7% above estimates on average.

Wall Street analysts project Puma Biotechnology, Inc. revenue of about $226.0M for fiscal 2026, with EPS near $0.38.

Over the past six months, Puma Biotechnology, Inc. insiders filed 15 SEC Form 4 transactions — 8 sales and 7 purchases. On net that is roughly 48K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

PBYI Financials

PBYI Latest News

PBYI Analyst Consensus

PBYI MoonshotScore

Common Questions About PBYI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources